Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr 7;15:227. doi: 10.1186/s12885-015-1259-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Gabriel et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Platinum-based chemotherapeutic agents affect MDM2 and VEGF pre-mRNA splicing. A-D: MCF7 and Ishikawa cells were treated with the indicated concentrations of cisplatin and harvested after 24 hours. E: MCF7 cells treated with cisplatin (50 μM) were harvested at the indicated times. F: The indicated cells were treated with cisplatin (50 μM) for 24 hours. G: MCF7 cells were treated with oxaliplatin at 50 μM and harvested after 24 hours. Analysis of the splicing of MDM2 (A,B,E-G) or of VEGF-A (C,D) transcripts was performed by end-point RT-PCR and acrylamide gel electrophoresis as detailed in Methods. Illustrated gels are representative of three independent experiments. FL: Full Length; ALT1: Splice variant of MDM2.